Moving toward personalized medicine in castration-resistant prostate cancer.

Urol Clin North Am
Authors
Keywords
Abstract

Recent advances in research technologies have allowed improved molecular characterization of castration-resistant prostate cancer (CRPC). These efforts hold promise for development of therapies that target alterations unique to an individual patient's prostate cancer. Targets include androgens and the androgen receptor pathway, pathways associated with hormone-resistant disease, and the immune system. In aggregate, this will allow physicians to choose treatments based on a particular tumor profile. As these approaches are developed, CRPC treatment is becoming an example of truly personalized medicine.

Year of Publication
2012
Journal
Urol Clin North Am
Volume
39
Issue
4
Pages
483-90
Date Published
2012 Nov
ISSN
1558-318X
URL
DOI
10.1016/j.ucl.2012.07.005
PubMed ID
23084525
Links